Neumora Therapeutics, Inc. Common Stock
$1.75
-0.57%Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -1.2).
Valuation inputs: P/E -1.2, earnings yield N/A, momentum -0.6%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -2.3%, ROIC -1.5%).
Profitability stack: net margin 0.0%, ROE -2.3%, ROIC -1.5%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +45.6%, momentum -0.6%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Neumora Therapeutics, Inc. Common Stock Market vs Earnings Trajectory
Loading price and EPS data...
Neumora Therapeutics, Inc. Common Stock Fair Value Envelope
No Revenue Data
NMRA has not reported any revenue values in the available annual periods.
Neumora Therapeutics, Inc. Common Stock Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
NMRA has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
NMRA has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
NMRA has not reported any net profit margin values in the available annual periods.
Neumora Therapeutics, Inc. Common Stock Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
FCF Growth Trend
Declining FCF warrants attention. Investigate whether due to temporary factors or fundamental deterioration.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Neumora Therapeutics, Inc. Common Stock Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Neumora Therapeutics, Inc. Common Stock Street Expectations Map
Wall Street analysts project that NMRA stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 7.00, with estimates ranging from a low of 6.00 to a high of 8.00.
The consensus 1-year price target stands at 7.00, with estimates ranging from a low of 6.00 to a high of 8.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Neumora Therapeutics, Inc. Common Stock Insider Positioning
During the last 12 months, insiders have purchased $15.00M and sold $390K worth of NMRA shares, resulting in $14.61M of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
23.4K
82.59K
-83K
-$83K
6-9 Months
5.7M
15.00M
114.7K
307.02K
+14.7M
+$14.69M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Burow Kristina
Director, 10 Percent Owner:
$5.00M
Arch Venture Partners X, Llc
10 Percent Owner
$5.00M
Arch Venture Partners Xii, Llc
10 Percent Owner
$5.00M
Top Sellers
Aurora Daljit Singh
Officer: See Remarks
$329K
Berns Paul L
Director, Officer: See Remarks
$34K
Pinto Joshua
Officer: President
$21K
Milligan Michael Lee
Officer: See Remarks
$5K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $14.61M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Insider Participation
4 insider sellers vs. 3 buyers. More insiders selling than buying suggests cautious or negative sentiment.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
No Dividend Yield Data
NMRA has not reported any dividend yield values in the available annual periods.
nmra Dividend History
Learning Layer
Related Guides
Build conviction on NMRA by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.